Home / Weight & metabolism / Semaglutide
SeApproved drug

Semaglutide protocol

A once-weekly GLP-1 agonist. Approved as Ozempic (type 2 diabetes) and Wegovy (weight management), including a 7.2 mg Wegovy HD dose approved in the US in March 2026.

Approved · Ozempic, Wegovy, Wegovy HDLabel schedule below
ProtocolMixingResultsSide effectsHow it worksSources

The protocol at a glance

Once a week, same day each week. The weight-management label steps up every 4 weeks over 16 weeks to reduce stomach side effects.

WeeksWeekly amount on the Wegovy label
1–40.25 mg
5–80.5 mg
9–121 mg
13–161.7 mg
17+2.4 mg maintenance (1.7 mg if 2.4 is not tolerated)
Optional7.2 mg (Wegovy HD) after at least 4 weeks at 2.4 mg

Diabetes (Ozempic): 0.25 mg for 4 weeks, then 0.5 mg, with optional increases to 1 mg and 2 mg.

Community reports

Community reports mostly follow the label steps from 0.25 mg, often staying at each step longer than 4 weeks when nausea is strong.

What people say they do, collected from community discussions. Not tested in a trial; shown so you can compare it with the evidence above.

Mixing calculator

Enter the vial size, the water you add and the amount you want to draw; it gives the mark on a 100-unit (1 mL) insulin syringe.

Draw to – units

What the trials found

Average body-weight change in the main obesity trials:

−14.9%2.4 mg · 68 wks (STEP 1)
−2.4%Placebo (STEP 1)
about −21%7.2 mg · 72 wks (STEP UP)
1,961adults in STEP 1

STEP 1: Wilding JP et al., N Engl J Med 2021 (NCT03548935). STEP UP figures as reported at the FDA approval of Wegovy HD, March 19, 2026.

Side effects

  • Nausea, diarrhoea, vomiting, constipation and stomach pain are the most common, mostly during step-ups.
  • Label warnings include thyroid C-cell tumours (seen in rodents), pancreatitis, gallbladder problems, kidney problems from dehydration and diabetic eye changes in people with diabetes.
  • Unusual skin sensations were more common at 7.2 mg in STEP UP.

How it works

GLP-1 receptor

Slows stomach emptying, lowers appetite and helps insulin release after meals.

Sources

  • Wegovy and Ozempic US prescribing information
  • Wilding JP et al. N Engl J Med 2021 (STEP 1, NCT03548935)
  • FDA approval of Wegovy HD 7.2 mg, March 19, 2026